[D-Arg25]-Neuropeptide Y (human)

[D-Arg25]-Neuropeptide Y (human) ([D-Arg25] NPY) is a Y1 receptor selective agonist. Neuropeptide Y (human) is involved in Alzheimer's disease (AD) and protects rat cortical neurons against β-Amyloid toxicity[1].

Product Specifications

UNSPSC

12352209

Target

Neuropeptide Y Receptor

Type

Peptides

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/d-arg25-neuropeptide-y-human.html

Solubility

10 mM in DMSO

Smiles

O=C(N1[C@@H](CCC1)C(N[C@@H](CO)C(N[C@@H](CCCCN)C(N2[C@@H](CCC2)C(N[C@@H](CC(O)=O)C(N[C@@H](CC(N)=O)C(N3[C@@H](CCC3)C(NCC(N[C@@H](CCC(O)=O)C(N[C@@H](CC(O)=O)C(N[C@@H](C)C(N4[C@@H](CCC4)C(N[C@@H](C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(O)=O)C(N[C@@H](CCSC)C(N[C@@H](C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC5=CC=C(C=C5)O)C(N[C@@H](CC6=CC=C(C=C6)O)C(N[C@@H](CO)C(N[C@@H](C)C(N[C@@H](CC(C)C)C(N[C@H](CCCNC(N)=N)C(N[C@@H](CC7=CNC=N7)C(N[C@@H](CC8=CC=C(C=C8)O)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC(N)=O)C(N[C@@H](CC(C)C)C(N[C@@H]([C@@H](C)CC)C(N[C@@H]([C@H](O)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC9=CC=C(C=C9)O)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CC%10=CC=C(C=C%10)O)N

Molecular Formula

C189H285N55O57S

Molecular Weight

4271.68

References & Citations

[1]Kilian Kuhn, et al. Molecular Tools for the NPY Y4 Receptor Derived from the C-Terminus of hPP and from Argininamide-type Y1R Antagonists. zur Erlangung des Doktorgrades der Naturwissenschaften an der Fakultät für Chemie und Pharmazie der Universität Regensburg.|[2]Li-Ying Fu, et al. Neuropeptide Y inhibits hypocretin/orexin neurons by multiple presynaptic and postsynaptic mechanisms: tonic depression of the hypothalamic arousal system. J Neurosci. 2004 Oct 6;24 (40) :8741-51.|[3]Ambikaipakan Balasubramaniam, et al. Neuropeptide Y (NPY) family of hormones: progress in the development of receptor selective agonists and antagonists. Curr Pharm Des. 2003;9 (15) :1165-75.